# Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer

> **NCT03651219** · PHASE3 · UNKNOWN · sponsor: **Beijing Chest Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03651219
- **Lead sponsor:** Beijing Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-09-08
- **Primary completion:** 2019-08-08
- **Final completion:** 2020-08-08
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2018-08-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03651219

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03651219, "Mesylate Apatinib Combined With Irinotecan in Treatment of Recurrent Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03651219. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*